A study reports phase 2a results for Insilico’s rentosertib

A randomized, placebo-controlled study reported 12-week results for rentosertib in 71 patients with idiopathic pulmonary fibrosis. Insilico sponsored the study; the AI-discovered and designed candidate’s primary endpoint concerned adverse events, with lung-function measures secondary.